We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00099242
First Posted: December 10, 2004
Last Update Posted: October 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Novartis
December 10, 2004
December 10, 2004
October 13, 2017
November 2003
Not Provided
  • Change in cognition from baseline at week 24
  • Global clinical impression of change from baseline at week 24
Not Provided
Complete list of historical versions of study NCT00099242 on ClinicalTrials.gov Archive Site
  • Change from baseline at week 24 in activities of daily living
  • Change from baseline at week 24 in behavioral symptoms
  • Change from baseline at week 24 in global cognitive testing
  • Change from baseline at week 24 in executive function
  • Change from baseline at week 24 in attention
Not Provided
Not Provided
Not Provided
 
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Alzheimer's Disease
  • Dementia, Alzheimer Type
Drug: rivastigmine transdermal patch
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1040
January 2006
Not Provided

Inclusion Criteria:

  • Diagnosis of dementia of the Alzheimer's type
  • Males, and females who are surgically sterile or one year postmenopausal
  • A primary caregiver willing to accept responsibility for supervising the treatment

Exclusion Criteria:

  • Any condition (other than Alzheimer's) that could explain patient's dementia
  • An advanced, severe or unstable disease that may put the patient at special risk
  • Current diagnosis of active, uncontrolled seizure disorder or unstable cardiovascular disease
Sexes Eligible for Study: All
50 Years to 85 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Chile,   Czechia,   Denmark,   Finland,   Germany,   Guatemala,   Israel,   Italy,   Korea, Republic of,   Mexico,   Norway,   Peru,   Poland,   Portugal,   Puerto Rico,   Russian Federation,   Slovakia,   Sweden,   Taiwan,   United States,   Venezuela
Czech Republic
 
NCT00099242
CENA713D2320
Not Provided
Not Provided
Not Provided
Not Provided
Novartis Pharmaceuticals
Not Provided
Not Provided
Novartis
October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP